Abstract 14692: Growth Differentiation Factor 15 is a Risk Marker for First-Ever Stroke in Hypertensive Patients: A Community-Based Study
Background: The growth differentiation factor 15 (GDF-15) is induced after experimental brain injury in animal model and associated with adverse outcomes in patients with ischemic stroke. We tested to determine whether circulating GDF-15 could predict risk for first-ever stroke in hypertensive patients.
Methods: Circulating levels of GDF-15 were determined by enzyme linked immunosorbent assays in two community-based populations. The cross-sectional study includes 93 hypertensive patients with stroke (48% males) and 245 hypertensive patients without stroke (42% males). The cohort study includes a random sample population of 271 hypertensive subjects >40 years without a history of stroke (37% males).
Results: In the cross-sectional study, the median GDF-15 concentration was significantly higher in hypertensive patients with stroke than in hypertensive patients without stroke (866ng/L vs. 608ng/L, P<0.0001). After adjustment for stroke risk factors (age, sex, body mass index, smoking, total cholesterol, HDL-C, blood pressure, and diabetes mellitus), individuals in the highest quartile of GDF-15 (>1010ng/L) had a higher risk of stroke than did those in the lowest quartile (adjusted OR, 5.26; 95% CI, 2.0-13.9; P<0.001). In the cohort study, twenty-one first-ever strokes were documented during the 4-year follow-up. High level of baseline GDF-15 (>1010ng/L) was significantly associated with elevated risk for first-ever stroke (P=0.002). This association was of borderline significance after adjustment for traditional risk factors (HR=6.1; 95% CI, 0.9-43.6; P=0.07).
Conclusions: GDF-15 is elevated in hypertensive patients with stroke and could serves as a predictor for risk of first-ever stroke. GDF-15 is a promising new biomarker for risk stratification of hypertensive patients.
- © 2013 by American Heart Association, Inc.